Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK.
Int J Antimicrob Agents. 2010 Jul;36(1):66-8. doi: 10.1016/j.ijantimicag.2009.10.003. Epub 2009 Dec 21.
The prophylactic potential of the azalide azithromycin as well as the fluoroquinolones trovafloxacin and grepafloxacin was assessed for the control of infection with Brucella melitensis in an experimental mouse model, determined by reduction in splenic bacterial burden. Trovafloxacin showed limited protective efficacy when administered 2h following a low-dose B. melitensis challenge, whereas grepafloxacin was ineffective. In comparison, azithromycin provided significant control of infection both following low- and high-dose challenges. Overall, the data confirm the potential utility of azithromycin in the prophylaxis of brucellosis and suggest that neither trovafloxacin nor grepafloxacin would likely be valuable for post-exposure prophylaxis of Brucella infection.
评估了氮杂内酯类阿奇霉素以及氟喹诺酮类药物托氟沙星和格帕沙星对布鲁氏菌感染的预防潜力，通过减少脾内细菌负荷来确定。在低剂量布鲁氏菌攻击后 2 小时给予托氟沙星时，显示出有限的保护效力，而格帕沙星则无效。相比之下，阿奇霉素在低剂量和高剂量挑战后均能显著控制感染。总的来说，这些数据证实了阿奇霉素在预防布鲁氏菌病方面的潜在应用，并表明托氟沙星和格帕沙星都不太可能对布鲁氏菌感染的暴露后预防有价值。
